Aurobindo Pharma's ANDA213511 for Eluxadoline Receives AP Status
Aurobindo Pharma's application ANDA213511 for Eluxadoline has received Abbreviated Approval (AP) status from the FDA.
Therapeutic Area
Therapeutic area intelligence for IBS-D with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.